SLC5A2 and heart failure: <h4>Introduction</h4>Sodium-glucose cotransporter-2 inhibitors (SGLT2is) improve outcomes in patients with heart failure (HF) and are recommended to be initiated in the 6 weeks following an HF hospitalization.